Taghizadeh et al. [61] demonstrated the potential of gliclazide (a second-generation sulfonylurea hypoglycemic drug employed in the treatment of patients with insulin-dependent diabetes mellitus) to reduce the oxidative stress and both CASP-3 and NFκB activities. The gene discussed is NFKB1; the disease is diabetes mellitus.